To test whether FDFT1 regulates inflammatory T cell function, we used the squalene synthase inhibitor lapaquistat, a drug historically used to treat hypercholesterolemia, to target FDFT1 in an in vitro human tonsillar organoid model of T cell-dependent germinal center B cell differentiation and humoral immunity [68] (Fig. 5A). This evidence concerns the gene FDFT1 and Hypercholesterolemia.